STEPHANIE PARISH: Open Payments
NPI 1457076853 · SEARCY, AR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,711 in 156 payments from 13 companies in 2025. Trend: 2023 $2,809 · 2024 $2,703 · 2025 $2,711
Food & beverage: $2,711
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 36 | $608 |
| Neurocrine BioSciences, Inc. | 16 | $372 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 18 | $348 |
| Otsuka America Pharmaceutical, Inc. | 16 | $282 |
| Alkermes, Inc. | 18 | $234 |
| Teva Pharmaceuticals USA, Inc. | 12 | $176 |
| Lundbeck LLC | 11 | $171 |
| Vanda Pharmaceuticals Inc. | 10 | $144 |
| Janssen Pharmaceuticals, Inc | 8 | $143 |
| GlaxoSmithKline, LLC. | 4 | $81 |
Products named: VRAYLAR, CAPLYTA, INGREZZA, REXULTI, ARISTADA, INVEGA SUSTENNA, ABILIFY ASIMTUFII, UZEDY.
Industry payments across AR — which companies pay providers there.
